Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates

Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $5.02 per share in fourth-quarter 2023, missing the Zacks Consensus Estimate of$5.26. In the year-ago period, the company reported an adjusted loss of 7 cents per share.Total revenues in the reported quarter rose 4% year over year to $1.01 billion. Sales of Xywav, Epidiolex and Rylaze drove the upside. Total revenues were in line with the Zacks Consensus Estimate. Per management, this was the first time where the company achieved a billion dollars i ...